To what extent is the association between obesity and colorectal cancer risk mediated by systemic inflammation?
In the present study, we evaluated potential mediatory effects of inflammation, as reflected in elevated serum CRP levels, in the association between measures of general and abdominal obesity and CRC risk. Large sample size, comprehensive adjustment for potential confounders, and measured (vs self-r...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
10 January 2025
|
| In: |
Cancer communications
Year: 2025, Volume: 45, Issue: 4, Pages: 456-459 |
| ISSN: | 2523-3548 |
| DOI: | 10.1002/cac2.12659 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/cac2.12659 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/cac2.12659 
|
| Author Notes: | Fatemeh Safizadeh, Marko Mandic, Michael Hoffmeister, Hermann Brenner |
| Summary: | In the present study, we evaluated potential mediatory effects of inflammation, as reflected in elevated serum CRP levels, in the association between measures of general and abdominal obesity and CRC risk. Large sample size, comprehensive adjustment for potential confounders, and measured (vs self-reported) anthropometric measures were among the most important strengths of our study, while consideration of anthropometric measures and a single inflammatory biomarker only at baseline, a majorly white population which limits the generalizability, and potential residual confounding were among the limitations. Despite its limitations, our analysis underlines the importance to consider potential reverse causality in the analyses of the associations between adiposity, systemic inflammation and CRC risk. The patterns observed in our analyses excluding the initial four years of follow-up do suggest that factors other than CRP-defined systemic inflammation might play a more relevant role in mediating the increased CRC risk due to adiposity. A lower than previously assumed role of systemic inflammation for CRC risk could also partly explain the challenges and shortcomings of chemoprevention efforts with anti-inflammatory drugs like aspirin. |
|---|---|
| Item Description: | Gesehen am 30.09.2025 |
| Physical Description: | Online Resource |
| ISSN: | 2523-3548 |
| DOI: | 10.1002/cac2.12659 |